Alexander D Zider1, Xiaoyan Wang2, Russell G Buhr3, Worawan Sirichana4, Igor Z Barjaktarevic1, Christopher B Cooper5. 1. Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. 2. Division of General Internal Medicine and Health Services Research, Department of Medicine, University of California, Los Angeles, Los Angeles, CA. 3. Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA; Department of Health Policy & Management, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA. 4. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand. 5. Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA; Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. Electronic address: ccooper@mednet.ucla.edu.
Abstract
BACKGROUND: The mechanism by which various classes of medication reduce COPD exacerbation risk remains unknown. We hypothesized a correlation between reduced exacerbation risk and improvement in airway patency as measured according to FEV1. METHODS: By systematic review, COPD trials were identified that reported therapeutic changes in predose FEV1 (dFEV1) and occurrence of moderate to severe exacerbations. Using meta-regression analysis, a model was generated with dFEV1 as the moderator variable and the absolute difference in exacerbation rate (RD), ratio of exacerbation rates (RRs), or hazard ratio (HR) as dependent variables. RESULTS: The analysis of RD and RR included 119,227 patients, and the HR analysis included 73,475 patients. For every 100-mL change in predose FEV1, the HR decreased by 21% (95% CI, 17-26; P < .001; R2 = 0.85) and the absolute exacerbation rate decreased by 0.06 per patient per year (95% CI, 0.02-0.11; P = .009; R2 = 0.05), which corresponded to an RR of 0.86 (95% CI, 0.81-0.91; P < .001; R2 = 0.20). The relationship with exacerbation risk remained statistically significant across multiple subgroup analyses. CONCLUSIONS: A significant correlation between increased FEV1 and lower COPD exacerbation risk suggests that airway patency is an important mechanism responsible for this effect.
BACKGROUND: The mechanism by which various classes of medication reduce COPD exacerbation risk remains unknown. We hypothesized a correlation between reduced exacerbation risk and improvement in airway patency as measured according to FEV1. METHODS: By systematic review, COPD trials were identified that reported therapeutic changes in predose FEV1 (dFEV1) and occurrence of moderate to severe exacerbations. Using meta-regression analysis, a model was generated with dFEV1 as the moderator variable and the absolute difference in exacerbation rate (RD), ratio of exacerbation rates (RRs), or hazard ratio (HR) as dependent variables. RESULTS: The analysis of RD and RR included 119,227 patients, and the HR analysis included 73,475 patients. For every 100-mL change in predose FEV1, the HR decreased by 21% (95% CI, 17-26; P < .001; R2 = 0.85) and the absolute exacerbation rate decreased by 0.06 per patient per year (95% CI, 0.02-0.11; P = .009; R2 = 0.05), which corresponded to an RR of 0.86 (95% CI, 0.81-0.91; P < .001; R2 = 0.20). The relationship with exacerbation risk remained statistically significant across multiple subgroup analyses. CONCLUSIONS: A significant correlation between increased FEV1 and lower COPD exacerbation risk suggests that airway patency is an important mechanism responsible for this effect.
Authors: T A Seemungal; G C Donaldson; E A Paul; J C Bestall; D J Jeffries; J A Wedzicha Journal: Am J Respir Crit Care Med Date: 1998-05 Impact factor: 21.405
Authors: Christine R Jenkins; Paul W Jones; Peter M A Calverley; Bartolome Celli; Julie A Anderson; Gary T Ferguson; Julie C Yates; Lisa R Willits; Jörgen Vestbo Journal: Respir Res Date: 2009-06-30
Authors: D J Powrie; T M A Wilkinson; G C Donaldson; P Jones; K Scrine; K Viel; S Kesten; J A Wedzicha Journal: Eur Respir J Date: 2007-05-15 Impact factor: 16.671
Authors: Gregory J Feldman; Ana R Sousa; David A Lipson; Lee Tombs; Neil Barnes; John H Riley; Sadhana Patel; Ian Naya; Chris Compton; Bernardino Alcázar Navarrete Journal: Adv Ther Date: 2017-11-01 Impact factor: 3.845
Authors: Robert M Burkes; Amanda J Gassett; Agathe S Ceppe; Wayne Anderson; Wanda K O'Neal; Prescott G Woodruff; Jerry A Krishnan; R Graham Barr; MeiLan K Han; Fernando J Martinez; Alejandro P Comellas; Allison A Lambert; Joel D Kaufman; Mark T Dransfield; J Michael Wells; Richard E Kanner; Robert Paine; Eugene R Bleecker; Laura M Paulin; Nadia N Hansel; M Bradley Drummond Journal: Ann Am Thorac Soc Date: 2018-07
Authors: Kathrin Kahnert; Peter Alter; Tobias Welte; Rudolf M Huber; Jürgen Behr; Frank Biertz; Henrik Watz; Robert Bals; Claus F Vogelmeier; Rudolf A Jörres Journal: Respir Res Date: 2018-06-04